Browse PLA2G5

Summary
SymbolPLA2G5
Namephospholipase A2, group V
Aliases FRFB; GV-PLA2; PLA2-10; hVPLA(2); Ca2+-dependent phospholipase A2; phosphatidylcholine 2-acylhydrolase 5; Gr ......
Chromosomal Location1p36-p34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted.
Domain PF00068 Phospholipase A2
Function

PA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides. This isozyme hydrolyzes more efficiently L-alpha-1-palmitoyl-2-oleoyl phosphatidylcholine than L-alpha-1-palmitoyl-2-arachidonyl phosphatidylcholine, L-alpha-1-palmitoyl-2-arachidonyl phosphatidylethanolamine, or L-alpha-1-stearoyl-2-arachidonyl phosphatidylinositol. May be involved in the production of lung surfactant, the remodeling or regulation of cardiac muscle.

> Gene Ontology
 
Biological Process GO:0006575 cellular modified amino acid metabolic process
GO:0006631 fatty acid metabolic process
GO:0006633 fatty acid biosynthetic process
GO:0006636 unsaturated fatty acid biosynthetic process
GO:0006644 phospholipid metabolic process
GO:0006650 glycerophospholipid metabolic process
GO:0006654 phosphatidic acid biosynthetic process
GO:0006658 phosphatidylserine metabolic process
GO:0006663 platelet activating factor biosynthetic process
GO:0006690 icosanoid metabolic process
GO:0006691 leukotriene metabolic process
GO:0006820 anion transport
GO:0006869 lipid transport
GO:0008654 phospholipid biosynthetic process
GO:0010517 regulation of phospholipase activity
GO:0010518 positive regulation of phospholipase activity
GO:0010876 lipid localization
GO:0014074 response to purine-containing compound
GO:0015711 organic anion transport
GO:0015718 monocarboxylic acid transport
GO:0015908 fatty acid transport
GO:0015909 long-chain fatty acid transport
GO:0016042 lipid catabolic process
GO:0016053 organic acid biosynthetic process
GO:0019370 leukotriene biosynthetic process
GO:0032309 icosanoid secretion
GO:0033559 unsaturated fatty acid metabolic process
GO:0036148 phosphatidylglycerol acyl-chain remodeling
GO:0036149 phosphatidylinositol acyl-chain remodeling
GO:0036150 phosphatidylserine acyl-chain remodeling
GO:0036151 phosphatidylcholine acyl-chain remodeling
GO:0036152 phosphatidylethanolamine acyl-chain remodeling
GO:0043410 positive regulation of MAPK cascade
GO:0044283 small molecule biosynthetic process
GO:0045017 glycerolipid biosynthetic process
GO:0046394 carboxylic acid biosynthetic process
GO:0046456 icosanoid biosynthetic process
GO:0046469 platelet activating factor metabolic process
GO:0046470 phosphatidylcholine metabolic process
GO:0046471 phosphatidylglycerol metabolic process
GO:0046473 phosphatidic acid metabolic process
GO:0046474 glycerophospholipid biosynthetic process
GO:0046486 glycerolipid metabolic process
GO:0046488 phosphatidylinositol metabolic process
GO:0046683 response to organophosphorus
GO:0046942 carboxylic acid transport
GO:0050482 arachidonic acid secretion
GO:0051591 response to cAMP
GO:0060191 regulation of lipase activity
GO:0060193 positive regulation of lipase activity
GO:0070371 ERK1 and ERK2 cascade
GO:0070372 regulation of ERK1 and ERK2 cascade
GO:0070374 positive regulation of ERK1 and ERK2 cascade
GO:0071715 icosanoid transport
GO:0072330 monocarboxylic acid biosynthetic process
GO:0097164 ammonium ion metabolic process
GO:1903963 arachidonate transport
Molecular Function GO:0004620 phospholipase activity
GO:0004623 phospholipase A2 activity
GO:0005539 glycosaminoglycan binding
GO:0008201 heparin binding
GO:0016298 lipase activity
GO:0047498 calcium-dependent phospholipase A2 activity
GO:0052689 carboxylic ester hydrolase activity
GO:1901681 sulfur compound binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04014 Ras signaling pathway
hsa04270 Vascular smooth muscle contraction
hsa04972 Pancreatic secretion
hsa04975 Fat digestion and absorption
hsa00564 Glycerophospholipid metabolism
hsa00565 Ether lipid metabolism
hsa00590 Arachidonic acid metabolism
hsa00591 Linoleic acid metabolism
hsa00592 alpha-Linolenic acid metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-1482788: Acyl chain remodelling of PC
R-HSA-1482839: Acyl chain remodelling of PE
R-HSA-1482925: Acyl chain remodelling of PG
R-HSA-1482922: Acyl chain remodelling of PI
R-HSA-1482801: Acyl chain remodelling of PS
R-HSA-1483206: Glycerophospholipid biosynthesis
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-1483257: Phospholipid metabolism
R-HSA-1483166: Synthesis of PA
Summary
SymbolPLA2G5
Namephospholipase A2, group V
Aliases FRFB; GV-PLA2; PLA2-10; hVPLA(2); Ca2+-dependent phospholipase A2; phosphatidylcholine 2-acylhydrolase 5; Gr ......
Chromosomal Location1p36-p34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PLA2G5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolPLA2G5
Namephospholipase A2, group V
Aliases FRFB; GV-PLA2; PLA2-10; hVPLA(2); Ca2+-dependent phospholipase A2; phosphatidylcholine 2-acylhydrolase 5; Gr ......
Chromosomal Location1p36-p34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PLA2G5 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPLA2G5
Namephospholipase A2, group V
Aliases FRFB; GV-PLA2; PLA2-10; hVPLA(2); Ca2+-dependent phospholipase A2; phosphatidylcholine 2-acylhydrolase 5; Gr ......
Chromosomal Location1p36-p34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PLA2G5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0940.768
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.5150.324
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2240.62
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.9020.211
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3270.766
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.6120.245
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.7810.182
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.2640.144
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2660.774
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.8230.341
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.3770.23
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.6870.0119
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PLA2G5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPLA2G5
Namephospholipase A2, group V
Aliases FRFB; GV-PLA2; PLA2-10; hVPLA(2); Ca2+-dependent phospholipase A2; phosphatidylcholine 2-acylhydrolase 5; Gr ......
Chromosomal Location1p36-p34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PLA2G5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPLA2G5
Namephospholipase A2, group V
Aliases FRFB; GV-PLA2; PLA2-10; hVPLA(2); Ca2+-dependent phospholipase A2; phosphatidylcholine 2-acylhydrolase 5; Gr ......
Chromosomal Location1p36-p34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PLA2G5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PLA2G5.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPLA2G5
Namephospholipase A2, group V
Aliases FRFB; GV-PLA2; PLA2-10; hVPLA(2); Ca2+-dependent phospholipase A2; phosphatidylcholine 2-acylhydrolase 5; Gr ......
Chromosomal Location1p36-p34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PLA2G5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPLA2G5
Namephospholipase A2, group V
Aliases FRFB; GV-PLA2; PLA2-10; hVPLA(2); Ca2+-dependent phospholipase A2; phosphatidylcholine 2-acylhydrolase 5; Gr ......
Chromosomal Location1p36-p34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PLA2G5 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPLA2G5
Namephospholipase A2, group V
Aliases FRFB; GV-PLA2; PLA2-10; hVPLA(2); Ca2+-dependent phospholipase A2; phosphatidylcholine 2-acylhydrolase 5; Gr ......
Chromosomal Location1p36-p34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PLA2G5 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPLA2G5
Namephospholipase A2, group V
Aliases FRFB; GV-PLA2; PLA2-10; hVPLA(2); Ca2+-dependent phospholipase A2; phosphatidylcholine 2-acylhydrolase 5; Gr ......
Chromosomal Location1p36-p34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PLA2G5 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.